Information Provided By: 
Fly News Breaks for August 3, 2018
PCRX
Aug 3, 2018 | 07:45 EDT
As reported earlier, Needham analyst Serge Belanger upgraded Pacira to Buy from Hold with a $54 price target. The analyst points to "strong" Q2 performance of Exparel, where sales growth is accelerating while the company engages more of the anesthesiologist community. Belanger says the company's "fortunes began to change in April with the unexpected approval of the nerve block label", adding that last week's CMS proposal to unbundle the drug from ASC center surgeries may turn into another "significant" growth catalyst starting next year.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
